We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Poxel annonce la tenue d’une Assemblée Générale Mixte le 11 février 2025 à 9h00 et la mise à disposition des documents préparatoires Poxel annonce l’ajout d’une nouvelle résolution à l’ordre du...
Patent life covering Imeglimin in China extended to 2039 Ongoing partnership discussions to develop and market Imeglimin in China, the world's second largest type 2 diabetes market Regulatory...
Poxel eligible for royalties equaling 10% of all TWYMEEG® net sales for 20241 and a one-time sales-based payment of JPY 500 million (EUR 3.1 million2) Allocation of all revenues received to the...
Regulatory News : Au titre du contrat de liquidité confié par la société POXEL (Paris:POXEL) à ODDO BHF SCA, à la date du 31 décembre 2024, les moyens suivants figuraient au compte de liquidité :...
Regulatory News: Poxel (Paris:POXEL) : Conformément aux dispositions de l’article L.233-8 II du Code de Commerce et de l’article 223-16 du Règlement Général de l’Autorité des Marchés Financiers...
Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.2265 | 138.109756098 | 0.164 | 0.3985 | 0.164 | 1155063 | 0.21840273 | DE |
4 | 0.2605 | 200.384615385 | 0.13 | 0.3985 | 0.129 | 1125156 | 0.20098652 | DE |
12 | 0.0675 | 20.8978328173 | 0.323 | 0.3985 | 0.115 | 517177 | 0.20209267 | DE |
26 | -0.1295 | -24.9038461538 | 0.52 | 0.747 | 0.115 | 399416 | 0.34628564 | DE |
52 | 0.0055 | 1.42857142857 | 0.385 | 0.898 | 0.115 | 335922 | 0.4435472 | DE |
156 | -4.0495 | -91.204954955 | 4.44 | 4.75 | 0.115 | 177483 | 0.70316611 | DE |
260 | -11.5095 | -96.718487395 | 11.9 | 12.2 | 0.115 | 157487 | 2.62624591 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions